
SERENA-6 Prompts Earlier ESR1 Testing in Breast Cancer
Dr Wander discusses how SERENA-6 could reshape ctDNA testing and the timing of ESR1-directed treatment.
Repeat molecular testing is an increasingly important consideration for patients with hormone receptor–positive (HR+)/HER2-negative metastatic breast cancer following progression on a CDK4/6 inhibitor. However, emerging evidence suggests that identifying resistance mutations earlier could help clinicians adjust treatment before disease progression becomes clinically apparent.
During the 44th Annual
Historically, clinicians have typically repeated ctDNA testing at the time of clinical or radiographic progression. ESR1 mutations, which affect the gene encoding the estrogen receptor, are uncommon in untreated primary breast cancer but become more prevalent following aromatase inhibitor (AI) exposure. By the time patients experience progression in the second-line metastatic setting, ESR1 mutations may be detected in approximately 30% to 40% of cases.1
However, findings from the
The study demonstrated a progression-free survival benefit of approximately 7 months with the early treatment switch, raising questions about whether molecular monitoring should occur before conventional signs of progression emerge.2
Wander notes that clinicians have differing interpretations of the findings. Although some have raised concerns about the study design, including the lack of crossover, others have emphasized the positive patient-reported outcomes and molecular findings, including high rates of ctDNA clearance with earlier intervention. Ultimately, SERENA-6 supported the
Wander anticipates that molecular testing will become more frequent and increasingly integrated into treatment decision-making across early-stage and metastatic breast cancer. However, he emphasizes that clinical practice may continue to evolve as additional evidence emerges over the next 6 to 18 months.
REFERENCES
1. Liao CY, John J, Anyanwu P, Bhave MA, et al. Bridging biomarker testing to biomarker-driven targeted therapy: real-world ESR1 mutation testing patterns and prevalence in ER+, HER2− metastatic breast cancer. Mol Diagn Ther. 2026;30(6):957-67. doi:10.1007/s40291-026-00876-z.
2. Bidard FC, Mayer EL, Park YH, Janni W, et al. First-line camizestrant for emerging ESR1-mutated advanced breast cancer. N Engl J Med. 2025;393(6):569-80. doi:10.1056/NEJMoa2502929.
3. FDA grants accelerated approval to a new breast cancer treatment. FDA. September 4, 2026. Accessed November 17, 2026. https://tinyurl.com/4rhw6vub
Related to this article








